ReviewActa parasitologica2025
Genetic Manipulation Tools in Leishmania: From CRISPR/Cas9 to Vaccine Strategies for Disease Control.
Review in Acta parasitologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A comprehensive review of CRISPR-Cas9-mediated genome editing in Leishmania strains: methodologies, applications, challenges and future directions.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGene editing technologies have emerged as a crucial approach totackling parasitic infections. Recent research underscores the potential of protozoan parasites, including Leishmania, to utilize gene editing strategies, such as the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas (CRISPR-associated proteins)(CRISPR/Cas9) to edit parasite genomes, modify virulence factors, and alter host immune responses. This review aims to explore the potential of CRISPR/Cas9 in the study of Leishmania and Leishmaniasis, focusing on its applications in understanding mechanisms and developing novel editing strategies.
methodsThe immunological response of the mammalian host and the nature of the Leishmania parasites play essential roles in the formation and progression of parasitic diseases. Among alternative treatment strategies, CRISPR/Cas9 has attracted attention as a promising tool for introducing protective or therapeutic mutations in Leishmaniasis. This review will provide recent insights into the role of gene editing, especially CRISPR/Cas9, in host-pathogen interactions, intercellular communication, immunomodulation, and pathogenesis of Leishmania.
resultsCurrent findings reveal that CRISPR/Cas9 enables efficient modification of Leishmania genomes, providing valuable insights into parasite biology, host-pathogen interactions, intercellular communication, immunomodulation, and disease pathogenesis. Additionally, immunotherapeutic models are being investigated to explore the potential applications of CRISPR/Cas9 in theranostics.
conclusionCRISPR/Cas9 has attracted attention as a promising tool for introducing protective or therapeutic mutations in Leishmaniasis. Integrating CRISPR/Cas9 with Leishmania-related research opens new avenues for disease control and understanding, while biologically inspired immunomodulatory strategies highlight its emerging role in next-generation parasite-targeted immunotherapy.
Indexed as
Identifiers
41238927What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.